FindTrial
Sign In

Treating epidermal growth factor receptor inhibitors-related skin xerosis by traditional Chinese medicine

Application of Zizao Yangrong Granules for Treating EGFRIs-related Skin Xerosis: a Randomized Double-blinding Controlled Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-17013498
Enrollment
Unknown
Registered
2017-11-23
Start date
2016-05-12
Completion date
Unknown
Last updated
2018-11-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anticancer targeted drugs-related skin xerosis

Interventions

experimental group:Zizao Yangrong granules+vitamin E ointment
controlled:placebo+vitamin E ointment

Sponsors

China-Japan Friendship Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. patients with malignant tumor confirmed by pathology or cytology; 2. patients with application of EGFRIs; 3. patients with EGFRIs-related skin xerosis; 4. no severe dysfunction of heart, liver, or kidney; 5. aged 18 to 85 years; 6. no mental disorders and normal language ability; 7. patients understand and agree to receive the treatment, and sign information consent form.

Exclusion criteria

Exclusion criteria: 1. patients with EGFRIs discontinuance; 2. patients without EGFRIs-related skin xerosis; 3. patients with allergic constitution; 4. patients with poor compliance.

Design outcomes

Primary

MeasureTime frame
the skin xerosis grade;the pruritus grade;—

Secondary

MeasureTime frame
the quality of life;the water content of skin;—

Countries

China

Contacts

Public ContactCui Huijuan

China-Japan Friendship Hospital

cuihj1963@sina.com+86 13911835018

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026